// App-Quantinova.ai

534 : Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.

Researchers

Presenter

  • Vladislav Berdunov

Principal Investigators

  • Steve Millen

  • Andrew Paramore

  • Sarah Reynia

  • Nina Fryer

  • Jane Griffin

  • Nadia Georges

Medical Centers

  • Pfizer Ltd, London, United Kingdom

  • Exact Sciences, London, United Kingdom

  • Jane Griffin Associates, East Molesey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved